Anna Bogacz

Dr. Anna Bogacz

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Fitoterapia
Verified
Journal Article
Closed access
Marcin OżarowskiMarcin Ożarowski
Marcin Ożarowski
Przemysław Łukasz MikołajczakPrzemysław Łukasz Mikołajczak
Przemysław Łukasz Mikołajczak
ABAnna Bogacz
Anna Bogacz
AGAgnieszka Gryszczyńska
Agnieszka Gryszczyńska
Małgorzata KujawskaMałgorzata Kujawska
Małgorzata Kujawska
Przemysław Łukasz MikołajczakPrzemysław Łukasz Mikołajczak
Przemysław Łukasz Mikołajczak

JSJerzy Sieńko
Jerzy Sieńko
IMIzabela Marczak
Izabela Marczak
MKMaciej Kotowski
Maciej Kotowski
ABAnna Bogacz
Anna Bogacz
KTKarol Tejchman
Karol Tejchman
KKKatarzyna Laura Kotfis
Katarzyna Laura Kotfis
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2), has triggered an enormous scientific response. Many studies have focused on understanding the entry of the SARS-CoV-2 virus into the host cell. The angiotensin-converting enzyme-2 (ACE2) is recognized as the host receptor used by SARS-CoV-2 to enter its target cells. Recent studies suggest that ACE2 gene polymorphisms might be candidates for genetic susceptibility to SARS-CoV-2 infection. The aim of this study is to evaluate the influence of ACE2 polymorphisms on COVID-19 disease risk and severity. In our study, we confirmed that there is a statistically significant increased risk of a more severe disease course of SARS-CoV-2 infection associated with the need for hospitalization in intensive care for patients with specific polymorphisms of the ACE2 gene. The most significant correlation was found for variant ACE2 rs2285666 (AA allele, OR = 2.12, p = 0.0189) and ACE2 rs2074192 (TT allele, OR = 2.05, p = 0.0016), and for ACE2 rs4646174 (GG allele, OR = 1.93, p = 0.0016), ACE2 rs4646156 (TT allele OR = 1.71, p = 0.008) and ACE2 rs2158083 (TT allele OR = 1.84, p = 0.0025). In conclusion, our findings identify that certain ACE2 polymorphisms impact the severity of COVID-19 disease independently of other well-known risk factors.

1 July 2020 in Clinical Interventions in Aging
Verified
Journal Article
Open access
PDF file
JSJerzy Sieńko
Jerzy Sieńko
MKMaciej Kotowski
Maciej Kotowski
ABAnna Bogacz
Anna Bogacz
KLKacper Lechowicz
Kacper Lechowicz
SDSylwester Drożdżal
Sylwester Drożdżal
KKKatarzyna Laura Kotfis
Katarzyna Laura Kotfis
Since the beginning of 2020, the whole world has been struggling with the pandemic of Coronavirus Disease 2019 (COVID-19) caused by a novel coronavirus SARS-CoV-2. The SARS-CoV-2 infection depends on ACE2, TMPRSS2, and CD147, which are expressed on host cells. Several studies suggest that some single nucleotide polymorphisms (SNPs) of ACE2 might be a risk factor of COVID-19 infection. Genotypes affect ACE2 structure, its serum concentration, and levels of circulating angiotensin (1-7). Moreover, there is evidence that ACE genotype affects the outcomes of acute respiratory distress syndrome (ARDS) treatment, the most severe consequence of SARS-CoV-2 infection. COVID-19 morbidity, infection course, and mortality might depend on ACE D allele frequency. The aim of this narrative review was to analyze and identify the mechanisms of ACE-I and ARBs with particular emphasis on angiotensin receptors and their polymorphism in the light of COVID-19 pandemic as these medications are commonly prescribed to elderly patients. There is no direct evidence yet for ACE-I or ARBs in the treatment of COVID-19. However, for those already taking these medications, both the European Society of Cardiology and the American College of Cardiology recommend continuing the treatment, because at present, there is no clear clinical or scientific evidence to justify the discontinuation of ACE-I or ARBs. Individualized treatment decisions should be based on the clinical condition and co-morbidities of each patient.

1 January 2015 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
Marcin OżarowskiMarcin Ożarowski
Marcin Ożarowski
BTBarbara Thiem
Barbara Thiem
Przemysław Łukasz MikołajczakPrzemysław Łukasz Mikołajczak
Przemysław Łukasz Mikołajczak
Anna PiaseckaAnna Piasecka
Anna Piasecka
PKPiotr Kachlicki
Piotr Kachlicki
TBTeresa Bobkiewicz-Kozłowska
Teresa Bobkiewicz-Kozłowska
Eryngium planumL. (EP) is as a rare medicinal plant with a lot of potentials as pharmaceutical crops. The aim of our study was to assess the effect of subchronic (28-fold) administration of a 70% ethanol extract of EP roots (200 mg/kg, p.o.) on behavioral and cognitive responses in Wistar rats linked with acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), and beta-secretase (BACE-1) mRNA levels and AChE and BuChE activities in the hippocampus and frontal cortex. On the last day of experiment, 30 min after the last dose of EP or Huperzine A (HU), scopolamine (SC) was given at a dose of 0.5 mg/kg b.w. intraperitoneally. The results of a passive avoidance test showed an improvement in long-term memory produced by the EP extract in both scopolamine-induced rats and control group. EP caused an insignificant inhibition of AChE and BuChE activities in the frontal cortex and the hippocampus. EP decreased mRNA AChE, BuChE, and BACE-1 levels, especially in the cortex. Our results suggest that the EP extract led to the improvement of the long-term memory in rats coupled with total saponin content. The mechanism of EP action is probably complicated, since HPLC-MS analysis showed 64 chemical compounds (phenolics, saponins) in the extract of EP roots.


9 December 2019 in Gynecological Endocrinology
Verified
Journal Article
Closed access
KOKatarzyna Ozegowska
Katarzyna Ozegowska
Joanna Bartkowiak-WieczorekJoanna Bartkowiak-Wieczorek
Joanna Bartkowiak-Wieczorek
ABAnna Bogacz
Anna Bogacz
ASAgnieszka Seremak-Mrozikiewicz
Agnieszka Seremak-Mrozikiewicz
ADAntoni J. Duleba
Antoni J. Duleba
LPLeszek Pawelczyk
Leszek Pawelczyk
This study was designed to investigate the relationship between the levels of select adipocytokines (adiponectin, visfatin and apelin) and angiotensin in converting enzyme (ACE) gene insertion/deletion (ID) polymorphism in lean women with and without polycystic ovary syndrome (PCOS). The PCOS group (N = 94) was identified according to the Rotterdam criteria. The Control group (N = 68) included age- and body mass index (BMI)-matched healthy volunteers. Serum levels of adipocytokines were measured using enzyme immunoassays (EIA) and ACE genes were evaluated by polymerase chain reaction (PCR). The PCOS group, when compared to the Control group had lower adiponectin (p < .001) but higher visfatin (p < .001) and apelin (p = .003). There was no significant correlation of the levels of these adipocytokines with BMI, fasting glucose, fasting insulin or Homeostasis Model Assessment-Insulin Resistance (HOMA-IR). The PCOS and the Control groups also differed with regard to the ACE ID genotype distribution (p < .001). The ID, DD, and II genotype frequencies were, respectively, 34, 57 and 9% in the PCOS group and 49, 22 and 29% in the Control group. When stratified according to individual ID genotypes, the levels of adipocytokines in the PCOS and the Control groups remained significantly different. There was no statistically significant relationship between the levels of adipocytokines and ACE ID genotypes.